AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7570257 — intervention group
Group type: COMPARATOR
Intervention: Orgotein infiltrations
Number of subjects: 68
Study 7570257 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Laser and Ultrasounds
Number of subjects: 68
Study 2287048 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-supervised home exercise program (2 km walk-jog exercise daily for 1 month, HR at 90-100% of anaerobic threshold)
Number of subjects: 183
Study 2287048 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 183
Study 6764859 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 60
Study 6764859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30840903 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (10 mg/kg)
Number of subjects: 0
Study 30840903 — intervention group
Group type: COMPARATOR
Intervention: Second intravenous immunoglobulin (IVIG) (2 g/kg)
Number of subjects: 0
Study 30840903 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-reported outcomes
Number of subjects: 0
Study 30927252 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive children with severe immunosuppression (CD4 category)
Number of subjects: 165
Study 30927252 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive children with advanced immunosuppression (CD4 category)
Number of subjects: 165
Study 30927252 — intervention group
Group type: COMPARATOR
Intervention: HIV-positive children on antiretroviral therapy (ART)
Number of subjects: 165
Study 30927252 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive children with nevirapine treatment
Number of subjects: 165
Study 27859546 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab (8-640 mg)
Number of subjects: 39
Study 27859546 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab (160-640 mg)
Number of subjects: 39
Study 27859546 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab (≥160 mg)
Number of subjects: 39
Study 27859546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 25480782 — intervention group
Group type: EXPERIMENTAL
Intervention: VA hospitals
Number of subjects: 2114
Study 25480782 — intervention group
Group type: COMPARATOR
Intervention: non-VA hospitals
Number of subjects: 2114
Study 25480782 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 2114
Study 23867729 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve growth factor (NGF) injections
Number of subjects: 12
Study 23867729 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (control)
Number of subjects: 12
Study 21458815 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 28
Study 21458815 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 28
Study 19228536 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative weight loss (10% or more of excess body weight)
Number of subjects: 100
Study 19228536 — intervention group
Group type: COMPARATOR
Intervention: No preoperative weight-loss requirements
Number of subjects: 100
Study 16817048 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Cystatin C (cysC)
Number of subjects: 75
Study 16817048 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Creatinine (Cr)
Number of subjects: 75
Study 16817048 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of cysC with hemoglobin
Number of subjects: 75
Study 16817048 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of cysC with cord blood pH
Number of subjects: 75
Study 16817048 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between cysC and Cr
Number of subjects: 75
Study 16817048 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of 1/cysC with Schwartz GFR
Number of subjects: 75
Study 12753335 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN/Riba and amantadine (Ama) including a 2‐week initial high IFN induction course (18 MU IFN daily) (group A)
Number of subjects: 37
Study 12753335 — intervention group
Group type: COMPARATOR
Intervention: Riba/Ama without IFN (group B)
Number of subjects: 37
Study 12753335 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative hepatitis C virus (HCV)‐RNA test result in transcription‐mediated amplification (TMA) at week 6
Number of subjects: 37
Study 11708608 — intervention group
Group type: EXPERIMENTAL
Intervention: SMLCT (structured medium- and long-chain triacylglycerols)
Number of subjects: 13
Study 11708608 — intervention group
Group type: COMPARATOR
Intervention: LCT (long-chain triacylglycerols)
Number of subjects: 13
Study 11708608 — intervention group
Group type: EXPERIMENTAL
Intervention: SMLCT
Number of subjects: 13
Study 11708608 — intervention group
Group type: COMPARATOR
Intervention: LCT
Number of subjects: 13
Study 9094919 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibration study with repeated food records or recalls
Number of subjects: 0
Study 9094919 — intervention group
Group type: COMPARATOR
Intervention: Large sample sizes with few food records per individual
Number of subjects: 0
Study 9094919 — intervention group
Group type: COMPARATOR
Intervention: Smaller samples with more records per subject
Number of subjects: 0
Study 8511862 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy (CT) in combination with therapeutic exercise
Number of subjects: 0
Study 8511862 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoelectrotherapy (CET) in combination with therapeutic exercise
Number of subjects: 0
Study 8511862 — intervention group
Group type: EXPERIMENTAL
Intervention: Single CT procedures
Number of subjects: 0
Study 8511862 — intervention group
Group type: EXPERIMENTAL
Intervention: Single CET procedures
Number of subjects: 0
Study 8511862 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical factors (CT and CET)
Number of subjects: 0
Study 3543794 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 60
Study 3543794 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 60
Study 3543794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30289105 — intervention group
Group type: EXPERIMENTAL
Intervention: Foreign-born participants
Number of subjects: 0
Study 30289105 — intervention group
Group type: COMPARATOR
Intervention: US-born participants
Number of subjects: 0
Study 30289105 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion of life spent in the US
Number of subjects: 0
Study 27613466 — intervention group
Group type: EXPERIMENTAL
Intervention: S0597 50 μg
Number of subjects: 222
Study 27613466 — intervention group
Group type: EXPERIMENTAL
Intervention: S0597 200 μg
Number of subjects: 222
Study 27613466 — intervention group
Group type: EXPERIMENTAL
Intervention: S0597 400 μg
Number of subjects: 222
Study 27613466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 25536515 — intervention group
Group type: COMPARATOR
Intervention: Volume-Controlled Mechanical Ventilation (CMV)
Number of subjects: 36
Study 25536515 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-Support Ventilation (PSV)
Number of subjects: 36
Study 23422221 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up LVEF measurements
Number of subjects: 449
Study 23422221 — intervention group
Group type: COMPARATOR
Intervention: No follow-up LVEF measurements
Number of subjects: 449
Study 23422221 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF improvement
Number of subjects: 449
Study 19952843 — intervention group
Group type: COMPARATOR
Intervention: Standard treadmill protocol (3.2 km·h(‐1), 2% increase per 2 min)
Number of subjects: 66
Study 19952843 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower workload treadmill protocols (2.0 km·h(‐1) and 2% increase every 2 min)
Number of subjects: 66
Study 19952843 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher workload treadmill protocols (4.4 km·h(‐1) and 2% increase every minute)
Number of subjects: 66
Study 18155534 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (EPO) dose
Number of subjects: 22955
Study 16846409 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (500,000 KIU) administered in two equal doses (before skin incision and added to the pump prime)
Number of subjects: 44
Study 16846409 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aprotinin)
Number of subjects: 44
Study 16846409 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (500,000 KIU)
Number of subjects: 44
Study 12848279 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 FA (fermented soybean milk with fish oil containing 600 mg of EPA and 260 mg of DHA/d for 12 weeks)
Number of subjects: 41
Study 12848279 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 FA (fermented soybean milk with fish oil)
Number of subjects: 41
Study 12848279 — intervention group
Group type: COMPARATOR
Intervention: Control (control soybean milk with olive oil)
Number of subjects: 41
Study 10726893 — intervention group
Group type: EXPERIMENTAL
Intervention: Dai‐kenchu‐to (DKCT)
Number of subjects: 6
Study 10726893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 9025399 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program on dysphagia for experimental group A
Number of subjects: 54
Study 9025399 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program on dysphagia for experimental group B (with deliberate reinforcement)
Number of subjects: 54
Study 9025399 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (both groups)
Number of subjects: 54
Study 9025399 — intervention group
Group type: COMPARATOR
Intervention: Reinforcement of program content for group B
Number of subjects: 54
Study 2082313 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ketorolac 30 mg
Number of subjects: 542
Study 2082313 — intervention group
Group type: COMPARATOR
Intervention: Morphine 6 mg
Number of subjects: 542
Study 2082313 — intervention group
Group type: COMPARATOR
Intervention: Morphine 12 mg
Number of subjects: 542
Study 363254 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) plus methotrexate (MTX) plus levamisole
Number of subjects: 107
Study 363254 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) plus methotrexate (MTX)
Number of subjects: 107
Study 363254 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) plus Baker's Antifol (BAF) plus levamisole
Number of subjects: 107
Study 363254 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) plus Baker's Antifol (BAF)
Number of subjects: 107
Study 363254 — intervention group
Group type: EXPERIMENTAL
Intervention: methyl‐CCNU (Me) plus methotrexate (MTX)
Number of subjects: 107
Study 363254 — intervention group
Group type: EXPERIMENTAL
Intervention: methyl‐CCNU (Me) plus Baker's Antifol (BAF)
Number of subjects: 107
Study 31891437 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure (GB30)
Number of subjects: 72
Study 31891437 — intervention group
Group type: COMPARATOR
Intervention: Control (no acupressure)
Number of subjects: 72
Study 31154626 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunogenic Yeast-Based Fermentation Product
Number of subjects: 0
Study 31154626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28692500 — intervention group
Group type: EXPERIMENTAL
Intervention: Spreader grafts (Group II)
Number of subjects: 30
Study 28692500 — intervention group
Group type: COMPARATOR
Intervention: No spreader grafts (Group I)
Number of subjects: 30
Study 25308434 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful eating training and online pre-ordering with price discounts
Number of subjects: 26
Study 25308434 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful eating training and online pre-ordering without price discounts
Number of subjects: 26
Study 25308434 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful eating training and online pre-ordering
Number of subjects: 26
Study 25308434 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed-treatment)
Number of subjects: 26
Study 23166149 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (E group)
Number of subjects: 46
Study 23166149 — intervention group
Group type: COMPARATOR
Intervention: Propofol (P group)
Number of subjects: 46
Study 21602313 — intervention group
Group type: EXPERIMENTAL
Intervention: Metreleptin (10 mg/day self-injected s.c.)
Number of subjects: 24
Study 21602313 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same volume and time as metreleptin)
Number of subjects: 24
Study 17853271 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 25
Study 17853271 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 25
Study 22929271 — intervention group
Group type: EXPERIMENTAL
Intervention: Social network site-based rating (Facebook)
Number of subjects: 2755
Study 22929271 — intervention group
Group type: COMPARATOR
Intervention: Internet-based rating
Number of subjects: 2755
Study 22929271 — intervention group
Group type: COMPARATOR
Intervention: Traditional live focus groups
Number of subjects: 2755
Study 16118493 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 21066
Study 16118493 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21066
Study 12899821 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intervention
Number of subjects: 0
Study 12899821 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention
Number of subjects: 0
Study 12899821 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal intervention
Number of subjects: 0
Study 9585710 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 10
Study 9585710 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lactate
Number of subjects: 10
Study 9585710 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10
Study 9585710 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil, Sodium lactate, Saline
Number of subjects: 10
Study 7650958 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric acupuncture treatment
Number of subjects: 54
Study 7650958 — intervention group
Group type: COMPARATOR
Intervention: Supportive medication (Control)
Number of subjects: 54
Study 2668246 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin plus azlocillin
Number of subjects: 202
Study 2668246 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime plus piperacillin
Number of subjects: 202
Study 2668246 — intervention group
Group type: COMPARATOR
Intervention: Azlocillin
Number of subjects: 202
Study 2668246 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin
Number of subjects: 202
Study 2668246 — intervention group
Group type: EXPERIMENTAL
Intervention: Double beta-lactam combinations
Number of subjects: 202
Study 728739 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg propranolol
Number of subjects: 14
Study 728739 — intervention group
Group type: COMPARATOR
Intervention: 100 mg metoprolol
Number of subjects: 14
Study 728739 — intervention group
Group type: EXPERIMENTAL
Intervention: propranolol
Number of subjects: 14
Study 728739 — intervention group
Group type: COMPARATOR
Intervention: metoprolol
Number of subjects: 14
Study 29361462 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 2.5 μg
Number of subjects: 102
Study 29361462 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 5 μg
Number of subjects: 102
Study 29361462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 26961964 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 95
Study 25694383 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist treatment (goserelin, 3.6 mg) starting 3-5 days postoperatively (Group O)
Number of subjects: 70
Study 25694383 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist treatment (goserelin, 3.6 mg) starting on days 1-5 of menstruation (Group M)
Number of subjects: 70
Study 25694383 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist treatment (Group M)
Number of subjects: 70
Study 25694383 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist treatment (Group O)
Number of subjects: 70
Study 23398254 — intervention group
Group type: EXPERIMENTAL
Intervention: Group decision influence on motor behavior precision
Number of subjects: 0
Study 23398254 — intervention group
Group type: COMPARATOR
Intervention: Conscious perceptual reports
Number of subjects: 0
Study 23398254 — intervention group
Group type: COMPARATOR
Intervention: Movement efficiency
Number of subjects: 0
Study 19889154 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic photodynamic therapy (PDT) treatments at 4- to 8-week intervals for 2 years.
Number of subjects: 12
Study 18594748 — intervention group
Group type: EXPERIMENTAL
Intervention: Crenotherapy treatment (vapour inhalation, aerosol and nasal douching) with thermal water for 14 days
Number of subjects: 120
Study 18594748 — intervention group
Group type: COMPARATOR
Intervention: Nasal douching and aerosol with saline twice a day for 14 days
Number of subjects: 120
Study 18594748 — intervention group
Group type: EXPERIMENTAL
Intervention: Crenotherapy treatment with thermal water
Number of subjects: 120
Study 15904751 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician sitting during consultation (video A)
Number of subjects: 69
Study 15904751 — intervention group
Group type: COMPARATOR
Intervention: Physician standing during consultation (video B)
Number of subjects: 69
Study 15904751 — intervention group
Group type: EXPERIMENTAL
Intervention: Second sequence of video (sitting then standing)
Number of subjects: 69
Study 12885707 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) from limeade, 25 mg consumed with each of 2 daily meals, 500 mL limeade twice a day, 6 days/week for 8 months
Number of subjects: 36
Study 12885707 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (lime-flavored beverage free of AA or citric acid)
Number of subjects: 36
Study 10485084 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional video on female condom use
Number of subjects: 100
Study 10485084 — intervention group
Group type: COMPARATOR
Intervention: Control group (no video)
Number of subjects: 100
Study 10485084 — intervention group
Group type: EXPERIMENTAL
Intervention: Female condom use
Number of subjects: 100
Study 8630579 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 micrograms of inhaled beclomethasone daily for 1 yr
Number of subjects: 32
Study 8630579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 2017011 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydraulic circuit training (HCT)
Number of subjects: 24
Study 2017011 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle training
Number of subjects: 24
Study 2017011 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising control group
Number of subjects: 24
Study 7318344 — intervention group
Group type: EXPERIMENTAL
Intervention: Remler M2000 sphygmomanometer
Number of subjects: 0
Study 7318344 — intervention group
Group type: COMPARATOR
Intervention: Hawkesley random-zero sphygmomanometer
Number of subjects: 0
Study 7318344 — intervention group
Group type: COMPARATOR
Intervention: LSH sphygmomanometer
Number of subjects: 0
Study 31318879 — intervention group
Group type: EXPERIMENTAL
Intervention: Local food basket
Number of subjects: 26
Study 31318879 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-Use Therapeutic Food (RUTF)
Number of subjects: 26
Study 27933348 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture (S34, S44, PC5) after NSAID intake
Number of subjects: 46
Study 27933348 — intervention group
Group type: COMPARATOR
Intervention: Control acupuncture (nonspecific points) after NSAID intake
Number of subjects: 46
Study 27933348 — intervention group
Group type: COMPARATOR
Intervention: Drug-based treatment (NSAIDs only)
Number of subjects: 46
Study 25686165 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber diet
Number of subjects: 240
Study 25686165 — intervention group
Group type: COMPARATOR
Intervention: AHA diet
Number of subjects: 240
Study 23713736 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 98
Study 23713736 — intervention group
Group type: COMPARATOR
Intervention: Control group (no electroacupuncture)
Number of subjects: 98
Study 21107432 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan 20 mg/Amlodipine 5 mg
Number of subjects: 120
Study 21107432 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan 20 mg/Hydrochlorothiazide 12.5 mg
Number of subjects: 120
Study 19808475 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation for atrial fibrillation (AF) in patients maintaining sinus rhythm (SR group)
Number of subjects: 78
Study 19808475 — intervention group
Group type: COMPARATOR
Intervention: Catheter ablation for atrial fibrillation (AF) in patients with recurrence of AF (AF group)
Number of subjects: 78
Study 17439538 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 2017
Study 17439538 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 30 mg intrarectal gel
Number of subjects: 2017
Study 17439538 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 2017
Study 15209480 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine for 12 months
Number of subjects: 588
Study 15209480 — intervention group
Group type: COMPARATOR
Intervention: Weight management program alone (Control)
Number of subjects: 588
Study 15209480 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 588
Study 10691230 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA (patient-controlled epidural analgesia) with a mixture of 0.125% bupivacaine and sufentanil
Number of subjects: 70
Study 10691230 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA (patient-controlled epidural analgesia)
Number of subjects: 70
Study 10691230 — intervention group
Group type: COMPARATOR
Intervention: PCA (patient-controlled analgesia) with intravenous morphine
Number of subjects: 70
Study 9344308 — intervention group
Group type: EXPERIMENTAL
Intervention: Training (walking with prosthesis, arm training at 60% workload, analytical exercises of the nonamputated leg)
Number of subjects: 10
Study 8458180 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 x 2.5 mg levoleucovorin tablets
Number of subjects: 68
Study 8458180 — intervention group
Group type: COMPARATOR
Intervention: 5 x 5 mg leucovorin tablets
Number of subjects: 68